Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.685 -0.025 (-1.46%)
Streaming Delayed Price Updated: 11:45 AM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

< Previous 1 2 3 4 5 Next >
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news 
Via InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
3 Cheap Biotech Stocks to Buy Now: May 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
Via AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest
 
Via Benzinga
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
Via AB Newswire
Topics Economy
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Via AB Newswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Via AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
Via AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
Via AB Newswire
Topics Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
Via AB Newswire
Topics Intellectual Property
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
ATNM stock offers moonshot or crash-landing possibilities as Actinium Pharmaceuticals works relentlessly to advance life-changing treatments. 
Via InvestorPlace
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
Via AB Newswire
Topics Intellectual Property
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
 
Via Benzinga
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer
Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Actinium CEO Sandesh Seth says the tumble this week had little to do with clinical data. 
Via Investor's Business Daily
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of... 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
 
Via Benzinga
What's Going On With Actinium Pharmaceuticals Stock?
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or... 
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.